PROCEDURE
Ultrasound and contrast agent
contrast-enhanced ultrasound combined with the gastrointestinal hormones Secretin and Cholecystokinin, which triggers the enzyme production of pancreas
Status
Unknown
Phase
Not applicable
Enrollment
80
Locations
1
Results
Not posted
Publications
0
Study summary
The purpose of this project is to evaluate and compare three new methods for diagnosis, staging, operability evaluation and treatment control of pancreas cancer. The investigators use contrast-enhanced ultrasound combined with the gastrointestinal hormones Secretin and Cholecystokinin, which triggers the enzyme production of pancreas. The hormones induce an increased metabolism and thus an increased blood flow through healthy pancreas tissue, however, not in tumor tissue. The investigators hope to be able to use this effect diagnostically. The patients included will also have a 64-slice-CT in order to evaluate, if an increased diagnostic safety can be reached compared to an older CT scanning method. All patients will also be examined for the tumor marker CA 19-9. Further, the investigators will examine if contrast-enhanced ultrasound can contribute with information in treatment control after either surgery or medical treatment.
Interventions
PROCEDURE
contrast-enhanced ultrasound combined with the gastrointestinal hormones Secretin and Cholecystokinin, which triggers the enzyme production of pancreas
Timeline
First posted
Nov 29, 2005
Study start
Feb 2005
Primary completion
Not reported
Study completion
Jan 2009
Results posted
Not reported
Registry updated
Feb 26, 2009
Outcomes
Not reported in the indexed record.
Not reported in the indexed record.
Eligibility
Inclusion Criteria: * suspicion of cancer of the pancreas
Study locations
Denmark. Showing up to 24 locations stored in the fast local snapshot.
Copenhagen University Hospital
Copenhagen, Denmark
Publications
No PMID-linked publications were present in this registry snapshot.
Related trials
Mayo Clinic · Exocrine Pancreatic Insufficiency · Chronic Pancreatitis
Phase 4
Recruiting
24
2026-07
Erasmus Medical Center · Liver Transplantation
Phase 1 / Phase 2
Enrolling by invitation
20
2026-06
Children's Hospital Medical Center, Cincinnati · Pancreatitis · Diabetes Mellitus
Phase 4
Enrolling by invitation
195
2026-03
University of California, Los Angeles · Anorexia in Adolescence
Not applicable
Recruiting
10
2026-02
M.D. Anderson Cancer Center · Pancreatitis
Not applicable
Recruiting
2,345
2025-10
Johns Hopkins University · Pancreas Cancer · Peutz-Jeghers Syndrome (PJS)
Phase 3
Recruiting
9,000
2025-10
The University of Texas Health Science Center at San Antonio · Post Bariatric Surgery · Gastric Bypass
Early Phase 1
Recruiting
200
2025-09
Adenocyte, LLC · IPMN, Pancreatic · Pancreas Cancer
Not applicable
Enrolling by invitation
500
2025-03
Related PeptideStat pages
Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.